tiprankstipranks
Trending News
More News >

CymaBay downgraded to Neutral from Buy at B. Riley

B. Riley analyst Mayank Mamtani downgraded CymaBay Therapeutics (CBAY) to Neutral from Buy with a price target of $32.50, up from $29, following the announcement of its proposed acquisition by Gilead (GILD) for $32.50 per share.

Don’t Miss TipRanks’ Half Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on CBAY:

Disclaimer & DisclosureReport an Issue

1